Prokaryotics is a biopharmaceutical company focused on the discovery and development of novel antibiotic classes.
Prokaryotics is a biopharmaceutical company focused on the discovery and development of novel antibiotic classes that target serious multi-drug resistant bacterial infections. Prokaryotics leverages deep knowledge of bacterial physiology, innovative screening strategies, and scientific excellence necessary to discover and develop new classes of antibiotics targeting outer membrane biogenesis - the fundamental armor erected by bacteria to naturally withstand the effects of antibiotics.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 8, 2018 | Grant | $2.50M | 1 | National Institutes of Health | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Institutes of Health | Yes | Grant |